ITRM
Iterum Therapeutics plc0.4020
-0.0190-4.51%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Q&A reaffirms launch, adds payer/sales color
Q&A largely reaffirmed prepared remarks on Orlynda's steady launch, committing to granular early reporting of prescriptions and prescribers before shifting to QoQ growth. Management eyed PBM formulary decisions by February after bid submissions, to lift fill rates from 16% lives coverage—one Medicare PBM deal already inked for 2026/2027. Virtual reps plus 10 in-field will efficiently hit 20+ territories. Inbound from non-target docs hints at wider pull, though they'll stick to uUTI promotion. No digital ads yet; field rules. Crisp answers eased metric and channel worries. Watch payer traction for 2026's $5M-$15M guide.
Key Stats
Market Cap
21.22MP/E (TTM)
-Basic EPS (TTM)
-0.72Dividend Yield
0%Recent Filings
8-K
Nasdaq MVLS deficiency notice
Iterum Therapeutics received a Nasdaq notice on December 11, 2025, for failing the $35 million MVLS requirement over 30 days, plus ongoing bid price and equity shortfalls. It has 180 days until June 9, 2026, to hit $35M MVLS for 10 straight days. No immediate delisting. Compliance hangs by a thread.
8-K
ORLYNVAH Q3 revenue: $0.4M
10-Q
Q3 FY2025 results
Iterum kicked off ORLYNVAH sales in August 2025, posting $0.4M net product revenue for Q3 FY2025 ended September 30, 2025—yet operating losses widened to $7.7M from $4.9M y/y amid ramped SG&A to $6.5M for commercialization. R&D eased 59% y/y to $1.3M as prior manufacturing costs shifted to inventory post-FDA approval. Cash dipped to $11.0M from $24.1M ytd, with $16.9M raised via equity offsetting $15.3M opex burn and $14.7M exchangeable note repayment; Pfizer promissory note stands at $21.2M due 2029 (10% rate post-extension). No free cash flow disclosed in the 10-Q. Going concern doubt persists with liquidity shortfall flagged.
8-K
ATM offering upsized $20M
Iterum Therapeutics filed a prospectus supplement on October 16, 2025, enabling up to $20 million in additional gross proceeds from selling 21,756,057 ordinary shares via its at-the-market agreement with H.C. Wainwright. Prior sales under the agreement totaled $36.2 million. ORLYNVAH launched in August 2025; modest sales expected this year. Funding bolsters early commercialization.
8-K
AGM elects director, rejects proposals
Iterum Therapeutics shareholders elected David Kelly as Class I director for a three-year term at the September 10, 2025 AGM, while ratifying KPMG as auditors. Say-on-pay failed. Shareholders rejected share capital increase, allotment authority, pre-emption opt-out, and equity plan expansion. Capital flexibility stalled.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
AZTR
Azitra Inc
0.30+0.00
EVFM
Evofem Biosciences, Inc.
0.01-0.00
INTI
Inhibitor Therapeutics Inc.
0.05-0.00
INVA
Innoviva, Inc.
19.92-0.22
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
SPRO
Spero Therapeutics, Inc.
2.27-0.02
TOVX
Theriva Biologics, Inc.
0.21+0.01
VIR
Vir Biotechnology, Inc.
6.48-0.24